Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2022-05-06 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings
2022-05-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Enlivex Therapeutics Ltd., pursuant to the Securities Exchange Act of 1934. It reports a press release about the issuance of U.S. patents, which is a regulatory announcement rather than a financial report or detailed filing. The document length is only 2100 characters, indicating it is a brief announcement rather than a full report. It does not contain financial statements or detailed analysis, nor does it announce voting results, management changes, or capital activities. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-05-05 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from Enlivex Therapeutics Ltd. to the SEC requesting acceleration of effectiveness of a Registration Statement on Form F-3. It references a specific filing (Form F-3) and a regulatory rule (Rule 461 under the Securities Act). The content is a formal regulatory communication related to a securities registration process, not a financial report, earnings release, or management discussion. The document length is short (1025 characters) and it is a correspondence letter, not a report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-05-03 English
Regulatory Filings 2022
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement of a report. Due to the lack of identifiable information and the fallback rule for documents that do not fit any specific category, the most appropriate classification is Regulatory Filings (RNS). The confidence is moderate given the inability to extract meaningful content.
2022-05-03 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a press release announcing the company's financial results for the year ended December 31, 2021, but the actual financial results are contained in the press release (Exhibit 99.1) which is incorporated by reference. The document itself is short (2061 characters) and primarily serves to furnish the press release rather than provide the full annual report or detailed financial statements. According to the rules, such a document is a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full annual report or detailed financial data itself. Therefore, the correct classification is Regulatory Filings (RNS).
2022-04-29 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form F-3 Registration Statement filed with the SEC, which is a type of shelf registration statement used by companies to register securities for public offering. It includes a prospectus describing the securities to be offered, terms of sale, risk factors, and other related information. This is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the registration statement itself, not just an announcement or a certification.
2022-04-29 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.